Sugi Predict

Sugi Predict / Compounds / SCHEMBL251629

SCHEMBL251629

SCHEMBL251629

CCCCCCCCCCCCCCCCCCOC(C)C(OCCCCCCCCCCCCCCCCCC)N(C)C

nearest known ligand 0.43

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
▸ SPHK1 Q9NYA1 1/20 0.43
▸ DNM1 Q05193 4/20 0.42
▸ LPAR1 Q92633 4/20 0.33
▸ LPAR3 Q9UBY5 4/20 0.33
▸ LPAR2 Q9HBW0 1/20 0.33
▸ USP2 O75604 1/20 0.32
▸ MEN1 O00255 1/20 0.32
▸ THRB P10828 1/20 0.32
▸ HTT P42858 1/20 0.32
▸ KMT2A Q03164 1/20 0.32
▸ MAPT P10636 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5561906 1.00 SPHK1 (0.43) SPHK1DNM1LPAR1LPAR3LPAR2
SCHEMBL251553 0.90 CNR1 (0.46) LPAR1LPAR3LPAR2
SCHEMBL251555 0.90 CNR1 (0.46) LPAR1LPAR3LPAR2
SCHEMBL945677 0.86 ALDH1A1 (0.54) —
SCHEMBL170865 0.86 ALDH1A1 (0.54) —
SCHEMBL2992709 0.82 SPHK1 (0.50) SPHK1DNM1LPAR1LPAR3LPAR2
SCHEMBL2988608 0.82 SPHK1 (0.50) SPHK1DNM1LPAR1LPAR3LPAR2
SCHEMBL2994688 0.82 SPHK1 (0.50) SPHK1DNM1LPAR1LPAR3LPAR2
SCHEMBL15346771 0.82 SPHK1 (0.50) SPHK1DNM1LPAR1LPAR3LPAR2
SCHEMBL2981074 0.82 SPHK1 (0.50) SPHK1DNM1LPAR1LPAR3LPAR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 416 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240358652-A1 LIPID NANOPARTICLE FORMULATIONS MONASH UNIVERSITY (AU) 2024-10-31 — — US claimed
EP-4387657-A1 LIPID NANOPARTICLE FORMULATIONS Monash University (AU) 2024-06-26 — — EP claimed
WO-2023019310-A1 LIPID NANOPARTICLE FORMULATIONS MONASH UNIVERSITY (AU) 2023-02-23 — — WO claimed
WO-2022115739-A1 — — 2022-06-02 — — WO claimed
US-9833416-B2 Oligonucleotide lipid nanoparticle compositions, methods of making and methods of using the same OHIO STATE INNOVATION FOUNDATION (US) 2017-12-05 — — US claimed
US-20160081944-A1 Oligonucleotide Lipid Nanoparticle Compositions, Methods of Making and Methods of Using the Same OHIO STATE INNOVATION FOUNDATION (US) 2016-03-24 — — US claimed
WO-2015154002-A1 OLIGONUCLEOTIDE LIPID NANOPARTICLE COMPOSITIONS, METHODS OF MAKING AND METHODS OF USING THE SAME OHIO STATE INNOVATION FOUNDATION (US) 2015-10-08 — — WO claimed
US-20260137630-A1 COMPOSITIONS AND METHODS FOR T CELL TARGETED DELIVERY OF THERAPEUTIC AGENTS AND ACTIVATION OF T CELLS THE TRUSTEES OF THE UNIV OF PENNSYLVANIA (US) 2026-05-21 — — US disclosed
WO-2026106695-A1 TARGETED NANOPARTICLES ENCAPSULATING WATER-SOLUBLE THERAPEUTICS, METHODS OF PRODUCTION, AND USE OPTIMEOS LIFE SCIENCES, INC. (US) 2026-05-21 — — WO disclosed
CN-122070139-A Composition for preventing or treating bladder cancer 基因特力株式会社 2026-05-19 — — CN disclosed
WO-2026102245-A1 MICROFLUIDIC MIXING DEVICES FOR HIGH-THROUGHPUT LIPID NANOPARTICLE (LNP) PREPARATION THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2026-05-15 — — WO disclosed
WO-2026102260-A1 CRISPR-RELATED METHODS AND COMPOSITIONS TARGETING ANGIOPOIETIN LIKE 3 (ANGPTL3) EDITAS MEDICINE, INC. (US) 2026-05-15 — — WO disclosed
CN-122029277-A Engineered class 2V-type CRISPR system 斯克里贝治疗公司 2026-05-12 — — CN disclosed
US-20110071208-A1 LIPID ENCAPSULATED DICER-SUBSTRATE INTERFERING RNA PROTIVA BIOTHERAPEUTICS, INC. (CA) 2011-03-24 — — US disclosed
EP-2279254-A1 NOVEL LIPID FORMULATIONS FOR NUCLEIC ACID DELIVERY Protiva Biotherapeutics Inc. (CA) 2011-02-02 — — EP disclosed
WO-2011011447-A1 COMPOSITIONS AND METHODS FOR SILENCING EBOLA VIRUS GENE EXPRESSION PROTIVA BIOTHERAPEUTICS, INC. (CA) 2011-01-27 — — WO disclosed
WO-2011000107-A1 NOVEL LIPID FORMULATIONS FOR DELIVERY OF THERAPEUTIC AGENTS TO SOLID TUMORS PROTIVA BIOTHERAPEUTICS, INC. (CA) 2011-01-06 — — WO disclosed
WO-2011000108-A1 COMPOSITIONS AND METHODS FOR SILENCING APOLIPOPROTEIN B PROTIVA BIOTHERAPEUTICS, INC. (CA) 2011-01-06 — — WO disclosed
US-20100130588-A1 NOVEL LIPID FORMULATIONS FOR NUCLEIC ACID DELIVERY PROTIVA BIOTHERAPEUTICS, INC. (CA) 2010-05-27 — — US disclosed
WO-2009127060-A1 NOVEL LIPID FORMULATIONS FOR NUCLEIC ACID DELIVERY PROTIVA BIOTHERAPEUTICS, INC. (CA) 2009-10-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260137630-A1 COMPOSITIONS AND METHODS FOR T CELL TARGETED DELIVERY OF THERAPEUTIC AGENTS AND ACTIVATION OF T CELLS LCP2, CD47, CD4 SPHK1 1186/4885DNM1 3927/4885LPAR1 60/4885
US-20240358652-A1 LIPID NANOPARTICLE FORMULATIONS LIPA, LIPC, PHOSPHO1 SPHK1 363/4885DNM1 1107/4885LPAR1 67/4885
US-20100130588-A1 NOVEL LIPID FORMULATIONS FOR NUCLEIC ACID DELIVERY SARNP, NPC1L1, SNRPE SPHK1 192/4885DNM1 351/4885LPAR1 23/4885
US-20110071208-A1 LIPID ENCAPSULATED DICER-SUBSTRATE INTERFERING RNA AGO2, RNASE1, MTREX SPHK1 504/4885DNM1 839/4885LPAR1 551/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.